Tan et al., in a study involving one hundred fifty-five patients with different advanced cancers, showed that the reduction in CTC counts and ratios of PD-L1-positive CTCs and PD-L1-high CTCs reflect a beneficial response to PD-1/PD-L1 inhibitors. This evidence concerns the gene CD274 and cancer.